Literature DB >> 35166140

A randomized controlled trial of 3,4-methylenedioxymethamphetamine (MDMA) and fear extinction retention in healthy adults.

Jessica L Maples-Keller1, Seth D Norrholm2, Mark Burton1, Collin Reiff3, Callan Coghlan1, Tanja Jovanovic2, Carly Yasinski1, Kathleen Jarboe1, Jeffrey Rakofsky1, Sheila Rauch1,4, Boadie W Dunlop1, Barbara O Rothbaum1.   

Abstract

BACKGROUND: Fear conditioning and extinction are well-characterized cross-species models of fear-related posttraumatic stress disorder (PTSD) symptoms, and recent animal data suggest that 3,4-methylenedioxymethamphetamine (MDMA) enhances fear extinction retention. AIMS: This study investigated the effect of MDMA on fear learning, extinction training, and retention in healthy humans.
METHODS: The study involved a randomized placebo-controlled, two-group, parallel design trial in a sample of healthy adults, age 21-55 recruited from a major metropolitan area. The experimental paradigm included a fear acquisition session followed by an extinction training session 24 hours later, and 2 hours after study drug administration. Fear extinction retention was measured 48 hours after extinction training. Participants (N = 34; 70.6% male and 29.4% female) were randomly assigned in 1:1 ratio to 100 mg MDMA or placebo. All randomized participants completed the trial and were included in primary analyses. Safety was monitored via adverse events and vital signs. MDMA was well-tolerated with no serious adverse events.
RESULTS: Results indicated a significant main effect of session between extinction training and retention with no significant group differences. Significantly more participants in the MDMA group retained extinction learning compared to the placebo group (χ2 = 7.29, p = 0.007).
CONCLUSION: Although we did not observe the hypothesized facilitation of extinction retention, the findings from this initial human trial provide compelling rationale to continue to explore the potential for MDMA to impact extinction retention.Clinical Trials Registry Name and Identifier: Evaluation of MDMA on Startle Response (NCT0318176) https://clinicaltrials.gov/ct2/show/NCT03181763?term = MDMA&draw = 2&rank = 9.

Entities:  

Keywords:  Fear extinction; MDMA; fear-potentiated startle; psychophysiology; randomized trial

Mesh:

Substances:

Year:  2022        PMID: 35166140     DOI: 10.1177/02698811211069124

Source DB:  PubMed          Journal:  J Psychopharmacol        ISSN: 0269-8811            Impact factor:   4.153


  3 in total

1.  Allosteric Binding of MDMA to the Human Serotonin Transporter (hSERT) via Ensemble Binding Space Analysis with ΔG Calculations, Induced Fit Docking and Monte Carlo Simulations.

Authors:  Ángel A Islas; Thomas Scior
Journal:  Molecules       Date:  2022-05-06       Impact factor: 4.927

2.  Effects of 3,4-Methylenedioxymethamphetamine on Conditioned Fear Extinction and Retention in a Crossover Study in Healthy Subjects.

Authors:  Patrick Vizeli; Isabelle Straumann; Urs Duthaler; Nimmy Varghese; Anne Eckert; Martin P Paulus; Victoria Risbrough; Matthias E Liechti
Journal:  Front Pharmacol       Date:  2022-07-13       Impact factor: 5.988

3.  Redefining the catalytic HECT domain boundaries for the HECT E3 ubiquitin ligase family.

Authors:  Emma I Kane; Steven A Beasley; Johanna M Schafer; Justine E Bohl; Young Sun Lee; Kayla J Rich; Elizabeth F Bosia; Donald E Spratt
Journal:  Biosci Rep       Date:  2022-10-28       Impact factor: 3.976

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.